Equipment For Lipid Nanoparticles Research – Fusion 4000 and Fusion 4000-X OEM Syringe Pumps

In connection with the development of mRNA-based vaccines against Coronavirus, lipid nanoparticles (LNPs) have shown to be a promising delivery form. Chemyx Fusion 4000 Syringe Pump and Fusion 4000-X OEM Syringe Pump have demonstrated outstanding performance for small-scale production of vaccine lipid nanoparticles.

The Chemyx Fusion 4000 Syringe Pump has the ability to allow for complex dual-rate, push-pull, pulseless, reproducible flow rates, and oscillatory flow requirements for research applications such as lipid nanoparticles. It has two pumps on one platform, is configured with dual motors, and two independently controlled precision syringe pump channels. Its programmable step-rate functionality makes it one of the most unique and advanced systems on the market.

Fusion 4000-X OEM Syringe Pump is a bolt-on microfluidic syringe pump module designed for integration into customer-made analytical instruments requiring precision flow functionality with removable syringes. With the same specifications of Fusion 4000 syringe pump, the Fusion 4000 OEM module is configured with dual motors and two independently controlled precision laboratory syringe pump channels that allow independent dual-rate, push-pull, pulseless, reproducible flow rates, and oscillatory flow requirements for difficult research applications such as lipid nanoparticles, microfluidic mixing, and microfluidic flow control in drug formulation applications.

Here is an example of how the Fusion 4000 Syringe Pump was used in the Delivery of mRNA vaccines with heterocyclic lipids to increase anti-tumor efficacy by STING-mediated immune cell activation published by Nature Biotechnology: Published on 30 September 2019 Author Lei Miao, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Here is another example of how the Fusion 4000 Syringe Pump was used in Synergistic lipid compositions for albumin receptor-mediated delivery of mRNA to the liver By Nature Communications. Author Lei Miao Published on 15 May 2020 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA

Have any questions or comments about this article? Fill out the form below and we'll get back to you as soon as possible!

Privacy & Terms

By choosing "I agree" below you agree to Chemyx Inc Terms of Service. You Also agree to our Privacy Policy, which describes how we process your information.